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Cancer-associated cells release citrate to support tumour
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Citrate is important for lipid synthesis and epigenetic regulation in
addition to ATP production. We have previously reported that cancer
cells import extracellular citrate via the pmCiC transporter to support
theirmetabolism.Here,weshowfor thefirst time that citrate is supplied
to cancer by cancer-associated stroma (CAS) and also that citrate
synthesisand release isoneof the latter’smajormetabolic tasks. Citrate
release from CAS is controlled by cancer cells through cross-cellular
communication. The availability of citrate from CAS regulated the cy-
tokine profile, metabolism and features of cellular invasion. Moreover,
citrate released by CAS is involved in inducing cancer progression
especially enhancing invasiveness and organ colonisation. In line with
the in vitro observations, we show that depriving cancer cells of citrate
using gluconate, a specific inhibitor of pmCiC, significantly reduced the
growth and metastatic spread of human pancreatic cancer cells in vivo
and muted stromal activation and angiogenesis. We conclude that
citrate is supplied to tumour cells by CAS and citrate uptake plays a
significant role in cancer metastatic progression.
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Introduction
Citrate is a central metabolite used by cancer cells for fatty acid
synthesis (Wang et al, 2016). One path of citrate synthesis is via the
reverse Krebs cycle (Metallo et al, 2011). We have recently discovered
that cancer cells can also import extracellular citrate by using a
plasma membrane citrate transporter (pmCiC; Mycielska et al, 2018).
This transporter has been cloned from the citrate releasing prostate
secretory epithelial cells (Mazurek et al, 2010) and determined to
change citrate transport direction, depending on the cell type in
which it is expressed (Mazurek et al, 2010; Mycielska et al, 2018).
Moreover, extracellular citrate can directly promote cancer prolif-
eration (Petillo et al, 2020) and alter metabolism in vitro (Mycielska
et al, 2018). In addition, pmCiC was found to be overexpressed in
human cancer cells compared with their benign counterparts in vivo,
where it was found to correlate with tumour grade, and was par-
ticularly increased at the invasion front and metastatic sites of tu-
mours of different origin (Mycielska et al, 2018). Daily application of a
specific pmCiC inhibitor, gluconate, slowed xenograft growth in vivo
by incompletely understoodmechanisms (Mycielska et al, 2018, 2019).
There is now extensive evidence that human cancer cells can in-
duce neighbouring stromal cells to produce proteins and metabolites
that aid tumour development, progression, and drug resistance
(Nazemi & Rainero, 2020). The metabolites documented include nu-
cleotides, lactate, and amino acids such as serine and glutamine
(Nazemi & Rainero, 2020), but the role of citrate in crosstalk between
tumour cells and the tumourmicroenvironment has hitherto not been
investigated in this regard. One route of citrate supplied to cancer
could be through blood. Citrate blood concentration is around 200 μM
(Mycielska et al, 2015). However, blood supply to growing tumours is
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often restricted and metastatic growth requires new blood vessel
formation. Another source of extracellular citrate could be tumour-
surrounding tissue known to have elevated citrate levels, for example,
benign prostate epithelium (Eidelman et al, 2017) or astrocytes in the
brain (reviewed by Mycielska et al [2015]).
Cancer-associated fibroblasts (CAFs) have already been shown
to support cancer metabolism by releasing several growth factors,
enzymes, and metabolites (Sakamoto et al, 2019). The main ob-
jective of this study was to determine whether CAFs/cancer-
associated stromal cells are the source of extracellular citrate to
cancer cells and the effects of extracellular citrate on cancer
metastatic progression.
We report evidence that CAFs are a substantial source of citrate
for cancer cells and that CAFs release citrate via the pmCiC. Im-
portantly, the metabolic activity of CAFs depends strongly on the
availability of citrate to cancer cells suggesting that citrate syn-
thesis and release is one of the main metabolic tasks of CAFs. We
also show that extracellular citrate plays a role in the induction of
an invasive phenotype and subsequent organ colonisation by
cancer cells. Consistent with this observation, daily treatment of
mice with gluconate (a specific inhibitor of pmCiC in cancer cells)
significantly reduced cancer spread, stromal transformation, an-
giogenesis, and increased immune infiltration. Citrate is, therefore,
a critical element of the cross-talk between cancer cells and
cancer-associated surrounding tissue and the presence of extra-
cellular citrate is crucial for metastatic progression.
Results
Availability of citrate to cancer cells determines metabolic
activity of CAFs
Human fibroblasts grown in control media versus media condi-
tioned by prostate cancer cell line PC-3M (CAFs) exhibited distinctly
different metabolic characteristics (Figs S1, S2, and 3A). One of the
metabolites which was released at a high level by CAFs was citrate.
CAFs also released significant amounts of panthotenate, biotin, and
proline. All these metabolites are involved in the support of fatty
acid synthesis (panthotenate), their metabolism (biotin), or protein
synthesis (proline). As observed earlier (Romero et al, 2015), we also
found that CAFs released increased amounts of several amino
acids. Analysis of conditioned media from cancer cells and un-
conditioned media showed that neither of them contained citrate
(Figs S1 and S3A). Therefore, it can be deduced that citrate present
in the media from transformed fibroblasts is exclusively due to the
synthesis and release from CAFs. Furthermore, the levels of py-
ruvate which can be used by cells for intracellular citrate synthesis
remained the same in the conditioned media from cancer cells and
fibroblasts, suggesting that pyruvate does not play a significant role
in CAF’s support of cancer metabolism.
Release of citrate indicated that this metabolite might play an
important role in the crosstalk between cancer cells and CAFs.
Therefore, we decided to study the differences in the way stroma is
transformed in response to cancer cells preincubatedwithout or with
extracellular citrate (CM PC-3M−cit and CMPC-3M+cit, respectively; Fig
S3B and C). Cancer cells were preincubated with, or without citrate for
48 h, and the medium was removed and replaced with the citrate-
free media used for conditioning for another 48 h. To determine the
effects of extracellular citrate only, under all experimental conditions
for cancer cells and fibroblasts and at each step of the experimental
procedure, glucose and glutamine were supplied in excess to allow
for unlimited intracellular citrate synthesis (Fig S3). Using the Sea-
horse instrument, we determined that CAFs transformed with the CM
PC-3M−cit media showed a significant increase in their O2 con-
sumption and glycolytic activity as compared with CAFs transformed
with the CM PC-3M+cit media (Fig 1A). Increased O2 consumption was
insensitive to mitochondrial blockers, suggesting non-mitochondrial
use of the oxygen. Correspondingly, there was also a significant
decrease in mitochondrial ATP synthesis. CAFs transformed by CM
PC-3M−cit expressed high level of glycolysis, whereas CAFs trans-
formedwith the CM PC-3M+cit media used predominantly OXPHOS to
synthesise ATP. Media from fibroblasts grown in either CM PC-3M−cit
or CM PC-3M+cit were then examined for citrate content. We found
that the level of citrate in media from fibroblasts stimulated with CM
PC-3M−cit were significantly higher (~300 μM, Fig 1B) than the con-
centration of citrate produced by fibroblasts stimulated with CM PC-
3M+cit (~200 μM). These data stay in line with the metabolic changes
(Fig 1A) where fibroblasts releasing more citrate showed higher
metabolic activity and a shift towards glycolysis.
It is important to note that no citrate was present in either of the
conditioned media used to transform fibroblasts (Fig S3); therefore,
the obtained results are exclusively due to the presence/absence
of extracellular citrate in the preincubation media of cancer cells.
Altogether, these data indicate that one of the crucial metab-
olites released by CAFs in support of cancer cells is citrate. The
amount of citrate released and in consequence CAFs metabolic
activity is determined by the availability of citrate to cancer cells.
Transformation of fibroblasts with conditioned media from the
PC-3M or L3.6pl (human prostate or pancreatic cancer cells, re-
spectively) resulted in the expression of pmCiC (Fig 1C; able to
transport citrate to the extracellular space as shown already in the
case of benign prostate epithelial cells; Mazurek et al, 2010).
Similarly, hepatic stellate cells, known to support metastases to
liver (Milette et al, 2017), incubated with conditioned media from
human prostate cancer PC-3M or human pancreatic L3.6pl cells
showed a significant expression of the pmCiC (Fig 1C). pmCiC ex-
pression was very low/negligible in fibroblasts and all hepatic
stellate cell lines measured under control conditions (where no
conditioned media from cancer cells were present; Fig 1C). It is
important to note that although LX2 and HSChTERT are permanently
activated human hepatic stellate cell lines, they only express pmCiC
after incubation with conditioned media from cancer cells.
Therefore, it can be concluded that citrate synthesis and release
from CAFs takes place only when it is induced by cancer cells.
To investigate the functional consequences of these metabolic
alterations, we next determined the differential expression of cy-
tokines under the above conditions. Cancer cells grown in the
presence of extracellular citrate largely released cytokines known
to stimulate tumour metastatic activity like MCP1 (Li et al, 2013), IL-8
(Yuan et al, 2005), and RANTES (Azenshtein et al, 2002; Figs 1D and
S4). On the other hand, cancer cells deprived of citrate released
cytokines largely associated with stromal transformation (Figs 1D
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Figure 1. Cancer-associated fibroblasts release citrate through pmCiC.
(A) Seahorse analysis of themetabolic characteristics and the energymap of fibroblasts grown inmedia used for conditioning, CM PC-3M−cit or CM PC-3M+cit (n = 4). The
graphs show differences between normal fibroblasts (white), fibroblasts transformed with CM PC-3M−cit (grey), and CM PC-3M+cit (black). (B) The graph depicts citrate
levels in the media from fibroblasts stimulated with CM PC-3M−cit (white) and CM PC-3M+cit (black). (C) pmCiC expression in fibroblasts and different hepatic stellate cell
lines grown in regular medium, low serummedium or transformed with conditioned media from PC-3M cells or L3.6pl cells. (D) The graphs show selected cytokines (n =
5) released from PC-3M cancer cells preincubated without or with extracellular citrate for 48 h (CM PC-3M−cit CM PC-3M+cit, respectively; upper panel) and human primary
skin fibroblasts transformed by CM PC-3M−cit CM PC-3M+cit (CM F-PC−cit and CM F-PC+cit, respectively; lower panel).
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and S4A–H). These includedMCP2,3, IL-5, TGFβs, and GROs (although
GROs are not statistically different between the groups). These
cytokines were either absent in the media from cancer cells
preincubated with citrate or expressed at a low level. GRO and
MCP2 and 3 are known to transform stroma (Yang et al, 2006;
Argyle & Kitamura, 2018; Sun et al, 2018), whereas IL-5 has been
shown to modulate tumour environment (Zaynagetdinov et al,
2015). TGFβs act on the tumour microenvironment by stimu-
lating the transformation of fibroblasts into myofibroblasts
(Papageorgis & Stylianopoulos, 2015). Release of these cyto-
kines suggests that cancer cells deprived of citrate concentrate
their efforts on transforming the surrounding stroma to get
metabolic support.
In response to CM PC-3M+cit, fibroblasts released several cyto-
kines (Figs 1D and S4) known to support cancer cell’s metastatic
behaviour such as IL13 (known to support cancer cell survival and
metastasis; Suzuki et al, 2015), MCP2,3 (Zhang et al, 2020), and RANTES
(Singh et al, 2018). CM PC-3M−cit also stimulated release of different
cytokines from fibroblasts but they tended (although not statistically
different) to be at a lower level (Figs 1D and S4).
Next, we investigated whether citrate induced any changes in PC-3M
metabolism that might account for the above phenotypes. PC-3M cells
incubated with extracellular citrate showed changes at the metabolite
levels. We have focused on the differences between the −citrate versus
+citrate groups. In the presence of extracellular citrate, cancer cells
decreased intracellular levels of metabolites associated with intracel-
lular citrate synthesis (reviewed by Haferkamp et al [2020]). In particular,
there was a comparatively low level of intracellular glutamate, gluta-
mine, but also glycine and serine (Fig 2A). Consistently, cancer cells
grown in themedia not supplemented with extracellular citrate showed
an increased release of citrate-synthesis related metabolites such as
lactate, serine, or acetylcarnitine (Fig S1). Compared with cancer cells
preincubated without citrate, extracellular citrate supply decreased
overall intracellular levels of metabolites shown best by total amounts
of different metabolic groups and ratios (Figs S5 and S6). This obser-
vation is consistent with a catabolic switch of cancer cells preincubated
with citrate for 48 h associated with increased invasive activity (epi-
thelial-mesenchymal transition [EMT]; Cha et al, 2015; Luo et al, 2017; Wu
et al, 2019).
We have also compared the intracellular metabolite levels of PC-
3M cells preincubated without or with extracellular 200 μM citrate,
with citrate and 150 μM gluconate and 150 μM gluconate alone (Fig
S7). A detailed statistical analysis confirmed differences between
the groups and indicated significant metabolites (derived from the
“variables of importance in projection” [VIP], Fig S7A and B). Sig-
nificant metabolites included citrate-synthesis related substrates
such as glutamine, glutamate, serine as well as total amino acid
levels consistent with the catabolic switch.
To check whether pmCiC expressed in cancer cells and in non-
cancerous cells differ in the inhibitor profile, we have performed
mitotoxicity assay. The mitotoxicity assay indicated that gluconate
at the highest concentrations and in the absence of extracellular
citrate is a mitochondrial toxin for PC-3M cancer cells (Figs 2B and
S8A). This mitotoxic effect was not observed when gluconate was
present in the media of benign cells (PNT2-C2; Fig S8B, fibroblasts;
Fig S8C, and different groups of CAFs; Fig S8D–G). The differences in
the inhibitor profile between exporting and releasing citrate pmCiC
would suggest some alteration in the structure or insertion of the
transporter between the two forms of the pmCiC.
We have already established (Mycielska et al, 2018) that cancer
cells grown in the presence of extracellular citrate (200 μM) change
their metabolism, whereas gluconate is a specific pmCiC blocker. Fig
2C shows that gluconate significantly alters citrate binding to
pmCiC. It appears that gluconate binding to pmCiC does not result
in a conformational change in pmCiC detectable by Trp fluores-
cence quenching (Fig S9A, green curve and blue curve). Citrate on
the other hand results in Trp quenching, exhibiting a Kd of 16 mM in
the absence of gluconate. Elevated Kd compared with the Km
values were reported also for other detergent solubilized trans-
porters (Khafizov et al, 2012). The Kd for citrate increases fourfold in
the presence of 100 mM gluconate (Fig 2C). The slope of the citrate/
gluconate titration suggests a further, likely allosteric, binding
event (Fig S9B). Docking of citrate and gluconate to the pmCiC
model locates gluconate on top of the central citrate binding site
(Fig 2C). At this position, gluconate binding would indeed not result
in any Trp quenching, for example, W215 is too far from a sulfur-
containing residue such as methionine. Consequently, gluconate
might increase the activation threshold while not blocking the
citrate binding site during transport in a competitive manner.
The presence of extracellular citrate affects cancer cell
metabolism and induces invasive phenotypes of cancer cells
We next tested how citrate affects markers known to correlate with
EMT, which would be consistent with increased tumour invasiveness
(Harner-Foreman et al, 2017) and mesenchymal–epithelial transition
(MET) associated with metastatic colonisation (Chao et al, 2010). A
48-h preincubation of cancer cells in extracellular citrate resulted in
a decreased Glut1, suggesting reduced glucose uptake. Together with
the increased expression of the ATP/ADP carrier, this change is
consistent with a switch towards OXPHOS (Fig 3A top left panel)
reported to be associated with EMT (Ippolito et al, 2016). 2 wk in-
cubation of cancer cells with extracellular citrate compared with
control conditions suggests a metabolic switch towards anaerobic
glycolysis consistent with proliferation/colonizing step (Faubert et al,
2020; as shown by increased Glut1 expression; Fig 3A top right panel).
Consistent with the acquisition of an invasive character as al-
ready shown by the metabolomic data and cytokine release, cancer
cells preincubated with citrate for 48 h showed an increased ex-
pression of Snail and vimentin (Fig 3A left, bottom, panel; Heldin
et al, 2012). The fact that only some increased EMT features were
observed is not surprising as PC-3M was derived from a prostate
carcinoma metastasis and likely is already invasive. A longer, 2-wk
incubation of cancer cells with extracellular citrate resulted in the
opposite effect and a decrease of some EMT markers, suggesting
changes consistent with MET and the colonisation stage (Fig 3A,
right, bottom panel). Scanning electron micrographs revealed that
also cell morphology was citrate dependent (Fig S10). A 48 h
preincubation of cancer cells with citrate resulted in more polar-
ized, highly invasive, spindle-shaped cells with higher number of
single and amoeboid cells known to correlate with the EMT phase
(Figs 3B and S10A; Friedl & Wolf, 2003; Morley et al, 2014).
In line with the colonisation step as indicated by themarkers (Fig
3A) PC-3M cells preincubated with citrate for 2 wk released mainly
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Figure 2. 48 h of preincubation with extracellular citrate induces intracellular metabolite changes.
(A) Heat map of the intracellular content of amino acids of PC-3M cells grown for 48 h under control conditions or in the media supplemented with 200 μM citrate. Each row
represents a separate repeat. (B)Mitotoxicity assay of different types of cells (PC-3M, PNT2-C2, human skinfibroblasts andfibroblasts transformedwith conditionedmedia fromPC-
3M cells preincubated under control conditions, with extracellular citrate, with gluconate and citrate or with gluconate alone; Fig S7, n ≥ 3) showed that when applied alone at high
concentration, gluconate has a cytotoxic effect on cancer cells. (C) Trp quenching at different concentrations of citrate and gluconate. Inset: Kd values determined from the Trp
quenching (red) andfluorescence change amplitudes (blue) in titrations of citrate in thepresenceof different concentrations of gluconate. Right panel: Possible inhibition of citrate
binding by gluconate binding to a second binding site predicted by a homology model (Mycielska et al, 2018). Spheres indicate Trp quenching radii by sulfur.
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Figure 3. Citrate in the extracellular space induces metabolic changes and contributes to the metastatic status of cancer cells.
(A) PC-3M cells were preincubated with or without extracellular citrate for either 48 h (left panel) or 2 wk (right panel). Western blots show typical expression of
metabolic transporters and EMT/mesenchymal–epithelial transition related proteins (n ≥ 3). The numbers under the Western blots show average normalised values
obtained using densitometric analysis; stars depict statistical significance. (B) The graphs (left) represent the number of single/ameboid shaped cells in cancer cells
preincubated with or without extracellular citrate for 48 h. The graphs on the right hand side show the differences in the number of cells with invadopodia between PC-
3M cells grown for 2 wk with or without extracellular citrate. For each condition at least 20 different areas from three repeats were analysed. Pictures were taken with the
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cytokines known to support stromal transformation like GROs, IL-8,
and IL-3 (Fig S4F). Cytokines released by PC-3M cells kept under
control conditions for 2 wk showed a similar pattern as already seen
after 48-h preincubation (compare Fig S4A with Fig S4E). This result
is consistent with the lack of disease progression/cancer cell
reprogramming as already determined by cell morphology and
Western blot analysis of cells under control conditions (Fig 3A).
Consequently, a similar pattern of cytokine release in CM
F-PC−cit after 2 wk and 48 h was also observed (compare Fig S4C
with Fig S4G). On the other hand, fibroblasts stimulated with CM PC-
3M+cit for 2 wk only released cytokines supporting angiogenesis
such as IL-6 and IL-3 (Dentelli et al, 2011; Nagasaki et al, 2014;
Masjedi et al, 2018) and metastasis formation/proliferation (MCP1,
Loberg et al, 2006) correlating with the colonisation process (Fig
S4D and H).
MET occurring under long term incubation of cancer cells with
extracellular citrate would also agree with the decreased (but not
significantly) expression of the ATP/ADP carrier and increased
Glut1 level suggesting an increase in glycolysis (Fig 3A). Increased
glycolysis and lactate release could enhance proliferation of the
colonizing cells (De la Cruz-López et al, 2019). 2-wk preincubation
with extracellular citrate resulted in highly spread/flattened
cells with long invadopodia, contacting the ECM (extracellular
matrix) and other cells consistent with the colonisation step (Figs
3B and S10B; Williams et al, 2019). Importantly, under controlled
conditions, cellular morphology remained unchanged at all
times. The morphology of cancer cells grown with citrate as
depicted with scanning electron microscopy seems also to in-
dicate increased fluidity of their plasma membrane. Consistently,
the level of total phosphatidylcholine, phosphatidylinositol,
sphingomyelin, and phosphatidylethanolamine (although the
last not significant) was increased in cancer cells grown with
citrate (Dawaliby et al, 2016; Fig 3C).
We have already shown that citrate appears only in the media
from CAFs and is not present at any significant level in the con-
ditioned media from cancer cells. However, conditioned media
from cancer cells contained significant amounts of cytokines,
known to support aggressive cancer behaviour. To test whether
cancer cell-derived cytokines and potentially other substrates are
sufficient to induce changes in cancer cells, we preincubated PC-3M
cells with CM PC-3M+cit or CM PC-3M−cit. We did not observe any
significant and consistent changes between the two groups of
cancer cells (Fig S11A). However, incubation of PC-3M cells with CM
F-PC+cit or CM F-PC−cit resulted in more pronounced differences in
cancer cells (Fig 3D). These results indicate that citrate released by
CAFs together with other elements might play a crucial role in
supporting cancer progression.
The data above show that stromal transformation depends on
the metabolic status of cancer cells. CAFs compensate for the lack
of metabolites and cytokines in cancer cells to support their
invasive and metastatic behaviour. From these data, we proposed
that citrate availability is an important requirement for tumour
progression and this was investigated further below.
Inhibition of pmCiC with gluconate in vivo decreases metastatic
spread and stromal transformation
To test the role of extracellular citrate uptake in metastasis, we
injected the lower spleen pole of athymic nude mice with human
pancreatic cancer L3.6pl cells. To avoid side effects of intrasplenic
“primary tumours,” the spleen was removed 15 min after tumour
cell injection. Gluconate blockade (daily in vivo injection) of citrate
uptake by metastasising human pancreatic cancer cells signifi-
cantly reduced metastasis rate (Fig 4A). Reduced metastatic spread
was accompanied by decreased stromal transformation (αSMA) as
shown in Fig 4B. Additional controls showed that gluconate or
citrate alone does not induce any changes in the αSMA expression
in fibroblasts grown under standard conditions (Fig S11B). Staining
with the anti-fibroblast–activating protein (FAP) antibody showed a
pronounced transformation of some stromal cells consistent with
hepatic stellate cells in the control group (Fig 4C; Wang et al, 2005;
Kaps & Schuppan, 2020). This was not observed in the case of
gluconate treated mice. Moreover, the size of metastases in the
gluconate-treated group was on average smaller with increased
immune infiltration (Fig 4D). Although FAP is not a typical immune
cell marker, its expression has been previously reported in sub-
populations of CD45+/CD45− cells (Jiang et al, 2016).
Treatment of mice injected subcutaneously with human pan-
creatic L3.6pl cells reduced tumour growth and more importantly
changed the metabolic characteristics of cancer tissues (Mycielska
et al, 2018). Changes in the tumour tissues were already visible from
the beginning of the experiment (Fig 5A, details in Mycielska et al
[2018]). Experimental tumours in mice treated with gluconate were
smaller, rounder, and paler compared to their untreated coun-
terparts. This observation is consistent with decreased angiogen-
esis (as shown by CD31 staining Fig 5B) accompanied by a significant
reduction of stromal transformation (α-SMA; Fig 5B). There was also
an increase in apoptosis which wasmost pronounced at the bottom
of the gluconate-treated tissues as determined by TUNEL staining
(Fig 5C). In mice treated with gluconate, there was an overall de-
crease in the expression of PDGFRβ and vimentin (Fig 5D) partic-
ularly at the tumour–stroma interface. Decreased levels of PDGFRβ
and vimentin in non-cancerous tissue are also consistent with
decreased stroma transformation (Fig 5C).
We have also performed a CAM assay (chorioallantoic mem-
brane) used as a 3D in vivo tumour model. Treatment of L3.6pl cells
with Na+-gluconate significantly reduced tumour growth and vol-
ume (Fig 5E) as compared with the control conditions where
equivalent volume of NaCl was used.
scanning electron microscope. (C) Measurement of phosphatidylcholine (PC), phopspahtidylinositol (PI), phosphatdylethanolamine (PE), and sphingomyelin (SM) in
cells under experimental conditions with or without extracellular citrate for 48 h (n = 4). (D) Western blot analysis of the expression of metabolic transporters and EMT/
mesenchymal–epithelial transition–related proteins of PC-3M cells grown for 48 h in themedia from fibroblasts transformedwith the conditionedmedia from PC-3M cells
preincubated for 48 h with or without extracellular citrate (CM F-PC−cit and CM F-PC+cit, respectively; right panel; n = 3). The numbers under the Western blots show
average normalised values obtained using densitometric analysis; stars depict statistical significance.
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Figure 4. Blocking of citrate uptake by cancer cells decreases metastasis rate in vivo.
Human pancreatic cancer L3.6pl cells were injected into the lower spleen pole of immunodeficient mice. 15 min after tumour cell injection, the spleen was removed.
Animals were daily intraperitoneally injected with sodium gluconate (500 mg/kg/d), respectively, NaCl. After 24 d, mice were euthanized, and livers and laparotomy
wounds were assessed. (A) Liver metastases were evaluated by a macroscopic score (0 = no tumour load; 1 = small singular tumours; 2 = large singular tumours; 3 =
confluent tumours in less than half of liver; 4 = confluent tumours in more than half of the liver; 5 = tumours in all liver segments). Hepatic tumour load was significantly
decreased (P = 0.046; n = 13 mice per group, one-tailed unpaired t test) in the treatment group (500 mg/kg/d sodium gluconate) compared with control group (NaCl).
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To conclude, depriving cancer cells of citrate by applying glu-
conate in vivo reduced the cancer growth and metastasis rate,
angiogenesis, and stromal transformation. Hence, blocking citrate
uptake in vivo might result in reduced capability of tumour to
progress.
pmCiC expression in cancer-associated cells in human cancerous
tissues
We next tested whether our in vitro data indicating that CAFs re-
lease citrate to support cancer metabolism can be extended to the
in vivo environment, by immunostaining analysis of human tissue
(Fig 6A–F). Analysis of human pancreatic (Fig 6A and C) and gastric
cancer glands (Fig 6B and D) as well as lymph node metastasis (Fig
6E) and lung metastasis (Fig 6F) of gastric cancer confirmed that
pmCiC is expressed not only in cancer cells of different organs
(Mycielska et al, 2018) but also in some subsets of fibroblasts in the
surrounding tumour environment. Moreover, we have also found
pmCiC expressed in some of the tumour micro-vessels. This would
be consistent with extracellular citrate playing a role in angio-
genesis by supporting vessel formation. To complete these studies,
we have assessed pmCiC expression in cancer cells and cancer-
associated stromal cells of human breast, gastric and pancreatic
tissues (Fig 6G). The highest expression of pmCiC in stromal cells
was observed in gastric and pancreatic cancers known to inten-
sively produce desmoplastic stroma as compared with other cancer
types (Hosein et al, 2020; Oya et al, 2020). Therefore, targeting pmCiC
might have an effect not only on cancer cells but also on the tu-
mour’s “infrastructure” (supporting cells).
Discussion
We have previously shown that cancer cells of different origin
take up extracellular citrate through the recently cloned pmCiC
(Mycielska et al, 2018). In the present study, we have explored the
source of citrate used by cancer cells and, importantly, its potential
role in tumour progression.
We have determined that CAFs, together with other cells from the
cancer environment such as hepatic stellate cells, express pmCiC
with the function of citrate release (summarised in Fig S12A and B).
Increased citrate synthesis by cancer-associated stroma (CAS) is
consistent with a recent report showing increased glutamine up-
take by cancer-associated cells rather than by cancer cells
themselves in vivo (Marin-Valencia et al, 2012).
Our data show that the metabolic activity of CAFs depends on
extracellular citrate availability to cancer cells; therefore, it is
regulated in the cancer environment. We propose that a lack of
extracellular citrate stimulates cancer cells to transform their
surroundings to get the necessary substrate. In support of this, we
show that cancer cells deprived of extracellular citrate for 48 h
release IL-6, which stimulates angiogenesis and GROs involved in
stromal transformation/senescence (Nagasaki et al, 2014; Masjedi
et al, 2018). Indeed, senescent fibroblasts which are known to be
part of the cancer environment (Yang et al, 2006; Mellone et al,
2017), have previously been shown to release high levels of citrate
(James et al, 2015). Therefore, cancer cells deprived of citrate may be
selected to release factors to stimulate their surroundings to com-
pensate for citrate deficiency. The organ colonisation step, as seen after
2 wk of incubation with extracellular citrate, was accompanied by a
release of IL-3, an angiogenesis-stimulating cytokine, complemented by
GROs responsible for the stromal transformation. Cancer cells grown
long term without citrate released similar cytokines at 48 h and 2 wk,
corroborating the hypothesis that citrate is necessary for metastatic
reprogramming. Previous studies have shown that other metabolites
such as lactate can also play a role in the communication between
cancer cells and CAFs (Whitaker-Menezes et al, 2011), but there is no
evidence that lactate alone can modify tumour behaviour. Conversely,
lactate can also be used for citrate synthesis (reviewed by Mycielska
et al [2015] and Haferkamp et al [2020]).
Persistent and long-term presence of citrate in the media of
cancer cells was shown to induce MET associated with growth and
colonisation (Brabletz, 2012). This would be consistent with ex-
tracellular citrate playing an additional signalling role, where the
constant presence of citrate might complete the process of stromal
transformation creating a niche ready for the metastatic growth.
Previous studies have shown that increased citrate levels precede
leptomeningeal carcinomatosis from lung cancer (An et al, 2015),
suggesting that cancer cells might transform distant stroma and
induce local citrate increase before metastatic processes begins.
The shorter incubation time of cancer cells with extracellular
citrate was shown to induce an invasive phenotype with some
features consistent with EMT. A similar effect on the protein level
was obtained when the cells were incubated with the media from
fibroblasts transformed by cancer cells deprived of citrate,
therefore induced to supplement this metabolite. This supple-
mentation of citrate by CAS and the induction of an activated fi-
broblast phenotype could have several implications regarding
potential cancer therapies. It is possible that the need for de novo
stromal transformation (e.g., after chemotherapy) could induce
metastatic processes (EMT and MET) through the local changes of
metabolite and cytokine levels and therefore modify the metastatic
behaviour of the remaining cancer cells.
Incubation of cancer cells with extracellular citrate decreased an
overall level of the metabolites tested. In particular, there was a
decrease of intracellular levels of substrates known to be involved
in intracellular citrate synthesis, including serine and glycine
(Possemato et al, 2011), glutamine and glutamate (Metallo et al,
2011). This would suggest that cancer cells without extracellular
citrate supply are forced to use several additional pathways to
(B) Pictures showing differences in the αSMA staining pattern inmetastasis in mouse livers treated with gluconate versus control. (C) Liver metastasis were stained with
the anti-fibroblast activating protein (FAP) antibody. Red arrows show stained area in the stroma consistent with cancer-associated cells, whereas blue arrows depict
immune cells expressing FAP. Enlarged pictures from the control group (on the right) show cells stained with anti-FAP antibody (in red) in the stroma (indicated with red
arrows) and immune cells (blue arrows). (D) Graphs showing average number of immune cells per total number of cells in the studied area. For these measurements
two border and two central areas were calculated per metastasis. For each experimental group, four different metastases were evaluated.
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Figure 5. Gluconate treatment in vivo increases apoptosis, decreases angiogenesis, stromal transformation, proliferation and expression of PDGRβ and vimentin in
cancerous tissues.
Human pancreatic cancer cells L3.6pl were injected subcutaneously in nude mice. Control mice were injected with saline and treated group with Na+-gluconate (as
described before, Mycielska et al, 2018). (A) Pictures of mice showing qualitative differences between the cancerous growths in treated versus untreated animals. The
photos cannot be used to compare tumour size. (B) Angiogenesis (CD31) and stromal transformation (αSMA) were also significantly decreased in the case of treated
animals. (C) Staining of the sections of tumours (TUNEL) show increased apoptosis in the treated group. Moreover, apoptotic regions were mainly observed at the lower
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account for the missing metabolite. Availability of extracellular
citrate decreases the levels of several metabolites which can be
considered as by-products of increased citrate synthesis
(Haferkamp et al, 2020). This metabolic change and more balanced
use ofmetabolic pathways are likely to contribute to the acquisition
of a more aggressive phenotype.
Although gluconate had some mitotoxic effects on cancer cells
when applied alone, it has to be noted that this effect was observed in
the presence of the highest concentrations of gluconate only, much
higher than those applied in our in vivo and in vitro experiments. It can
be therefore deduced that the effects of gluconate observed in the
experiments are due to its specific action on pmCiC and not through
some less specific mitochondrial blocking. Moreover, gluconate, till
now, has been considered as a physiologically neutral substance and
used in medicine as a heavy ion carrier (reviewed by Mycielska et al
[2019]). It is also used in electrophysiology and transport studies as a
Cl− replacement because it is plasma membrane impermeable (Carini
et al, 1997; Bonzanni et al, 2020).
Importantly, we have confirmed that depriving cancer cells of
extracellular citrate supply in vivo results in decreased metastatic
spread, stromal transformation and angiogenesis. Furthermore, we
have observed increased immune cell infiltration of the mouse
tumour xenografts treated with gluconate. FAP expressing immune
cells have been seen previously (Arnold et al, 2014; Cremasco et al,
2018) and considered to comprise CD45+ cells, which is consistent
with the increased proinflammatory cytokine release by cancer cells
deprived of extracellular citrate. Increased release of proin-
flammatory cytokines has been also associatedwith citrate uptake by
monocytes (Ashbrook et al, 2015), whereas activated macrophages
have been determined to accumulate citrate (Jha et al, 2015). This
could suggest that preventing cancer cells from taking up extra-
cellular citrate and consequently increasing local citrate concen-
tration might have a stimulating effect on anti-cancer immune
response. Although we found these results particularly interesting, it
has to be acknowledged that for this study, immunocompromised
mice have been used, and therefore, a more detailed study of im-
mune activity upon gluconate application was not possible.
To conclude, our results demonstrate that citrate is an important
metabolite supportive of tumour progression which is synthesized
and released by CAS. Moreover, citrate synthesis and release from
cancer-associated stroma appears to be one of their major met-
abolic tasks and is induced and controlled by cancer cells through
cross-cellular interactions. We have identified the transporter re-
sponsible for citrate release and confirmed its expression in
cancer-associated cells in human tissues. Blocking of citrate uptake
by cancer cells using gluconate, a specific inhibitor of citrate up-
take, reduced cancer spread and decreased stromal transformation
and angiogenesis in vivo.
Our novel finding of citrate release by cancer-associated stroma
is crucial in understanding the mechanism of tumour environ-
mental support and interactions between cancer cells and the
environment. It sheds new light on the mechanism of how stroma
stimulates metastatic spread, facilitates organ colonisation and
angiogenesis, as well as increases cancer cells’ resistance to anti-
cancer therapies. Inhibiting citrate release from CAS and/or uptake
by cancer cells could offer novel, specific, and readily implemented
options for cancer treatment and metastasis prevention.
Materials and Methods
Cell culture
Cell lines PC-3M, PNT2-C2, and L3.6pl were grown as described
previously (Mycielska et al, 2018). Adult human dermal primary
fibroblasts were derived from the skin biopsies of healthy donors as
described by Milenkovic et al (2018). Naive human hepatic stellate
cell line hHSC (iX Cells Biotechnologies) and two permanently
activated human hepatic stellate cell lines LX2 and HSChTERT (Meyer
et al, 2017) were cultured as depicted before (Schmidt et al, 2018).
The following chemicals were used: citric acid and Na+-gluconate
(Sigma-Aldrich), and dialyzed serum (PAN Biotech GmbH). The
following antibodies were used: pmCiC antibodies (Mazurek et al,
2010; custom-made by GenScript Inc.), SLC25A5, vimentin, Slug,
Snail, EGFR, E-cadherin, N-cadherin (Cell Signalling), SLC6A14, Glut1,
Ki67, pan cytokeratin (Abcam), TGFβ-RII, PDGFRα (Santa Cruz Bio-
technology), and TUNEL (R&D Systems). Experimental media con-
sisted of glucose-free Roswell Park Memorial Institute 1640medium
(RPMI-1640) (Lonza), 5% dialyzed serum, 2 mM glutamine, 0.5 g/l
glucose, and ±200 μM citrate, unless otherwise stated. The incu-
bation time varied between 48 h, 2 wk, and over 2 mo, as specified.
Western blots were analysed by measurement of the pixel density
using ImageJ software (Laboratory for Optical and Computational
Instrumentation [LOCI], University of Wisconsin-Madison).
For conditioning, the cells were plated at 1 × 106 (PC-3M) or 2 × 106
(L3.6pl) per T75 flask in regular growthmedia for 24 h (PC-3M) or 48 h
(L3.6pl). After that, they were incubated in RPMI or DMEM, re-
spectively, with 0.5% FBS and 2mM glutamine for 48 h (Fig S1). Media
were then collected, filtered, and supplemented with 2 g/l (PC-3M)
or 4 g/l (L3.6pl) glucose and 2 mM glutamine to avoid starvation.
Fibroblasts were grown in conditioned media for 72 h and collected
for further analysis. To study the extracellular citrate effect on fi-
broblast activation, PC-3M cells were preincubated in RPMI media
with 5%dialyzed serum, 2mM glutamine, 0.5 g/l glucose, and with or
without 200 μM citrate. After 48 h, media were changed to condi-
tioning media and the procedures were carried out as described
above. Hepatic stellate cells were exposed to regular medium (10%
FBS), low serum medium (1% FBS), and conditioned medium from
PC-3M and L3.6pl for 48 h (LX2, HSChTERT) or 72 h (hHSC); afterwards
cells were harvested and pmCIC expression was measured by
Western blot.
parts of the tissues. (D) Cancer cells proliferation in the tissues was decreased (Ki67), as well as PDGFRβ and vimentin expression. (E) The CAM assay was performed
using L3.6pl cells. The cells were left to grow for 2 d then NaCl was used in the control group and Na+-gluconate in gluconate group for 5 d. (1) Tumour explants after daily
treatment with NaCl (upper) or Na+-gluconate (lower). (2) Examples of tumour volume measurements with the 3D digital microscope (Keyence VHX-7000 microscope). (3)
Graphs showing changes in the tumour weight and tumour volume of NaCl versus gluconate treated groups.
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Figure 6. pmCiC is expressed in the stroma of human cancerous tissues.
(A, B) immunohistochemical staining of pmCIC showed strong expression in human pancreatic (A) and gastric cancer glands (B) (DAB—150 μm). (C, D) In close contact to
infiltrating cancer glands, there is also a prominent expression in micro-vessels (v) but also in spindle cells (→) of the tumour microenvironment (TME) in both cancer
types (C, D) (DAB,— 50 μm). The latter cell type of the TME could be identified by vimentin as tumour associated fibroblasts (data not shown). (E) Consecutive examination
of lymph node metastasis (E) (DAB—50 μm) demonstrate a positive tumour gland but also expression in micro-vessels (v) and fibroblasts. (F) The same was true for a
metastatic gastric cancer shown in figure (F) (DAB,— 50 μm). (G) A table showing the number/percentage of human tumour tissues expressing pmCiC in cancer cells and in
cancer-associated stroma cells.
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Seahorse assay
3 × 104 primary dermal fibroblasts cells were grown in XFp eight well
miniplates (Agilent Technologies) at 37°C, humidified air, and 5% CO2/
95% air. Cartridges were prepared according to the manufacture’s
recommendations. The XFp Cell Mito Stress Test Kit (Agilent Tech-
nologies) contained the mitochondrial stress compounds oligomycin
(1 μM), FCCP (2 μM), and rotenone/antimycin A (1 μM). Oxygen con-
sumption rate and extracellular acidification rate (ECAR) weremeasured
by means of an XFp Seahorse Flux Analyzer (Agilent Technologies) and
were normalised by cell number. Directly after measurement, the cells
were fixed and stained with Hoechst 33342. The cell number per well
were counted using ImageJ software.
Cytokine detection and citrate measurements
To measure the release of cytokines, Human Cytokine Antibody
Array from RayBiotech was used. Conditioned media were collected
from cancer cells as summarised in Fig S3. Cytokine values from the
unconditioned media used for conditioning were subtracted from
the values obtained in the media from cancer cells. Consequently,
cytokine levels in the media from cancer cells were subtracted from
the values obtained in the media from fibroblasts. The kit was used
according to the manufacturer’s instructions and analysed using
supplied positive and negative controls for all the assays. We used
the same control media for all conditions tested, and all the
membranes were prepared at the same time. The values between
different cell types were not compared, but the trend in cytokines
released is presented on separate graphs for all conditions tested.
Citrate in the media from fibroblasts was measured using
Citrate assay kit (Sigma-Aldrich) according to the manufacturer
instructions.
Inhibition of citrate binding to pmCiC analysed by fluorescence
quenching
pmCiC was expressed in Sf9 cells using the Baculo-Virus System.
Membranes were prepared by sequential centrifugation and sol-
ubilized with 2% vol/vol dodecylmaltoside. pmCiC was purified via
His-Tag Ni-NTA chromatography and brought to a final concen-
tration of 0.1 mg/ml for fluorescence quenching titration experi-
ments using a JASCO Cary Eclipse spectrometer. The excitation
wavelength was set to 285 nm, and emission was measured in
between 200 and 500 nm. Trp quenching was detected at different
concentrations of citrate in the absence and presence of gluconate.
Relative changes in the fluorescence amplitude at 375 nm was
plotted against citrate or gluconate concentration and fitted with
Hill equation. The double reciprocal plot of fluorescence change
against citrate concentration was fitted with a non-linear model. Kd
values were determined from rectangular hyperbolic binding
models and plotted against respective gluconate concentrations.
Amplitude, that is, the maximal change of fluorescence during
citrate titration was plotted against respective gluconate concen-
trations. A previously constructed homology model of pmCiC with
citrate and gluconate docked to it (Mycielska et al, 2018) was in-
vestigated by for putative TRP quenching radii by sulfur using the
program UCSF Chimera (Mycielska et al, 2018).
Non-targeted metabolomics
Non-targeted metabolomics analysis of the cell media was con-
ducted at the Genome Analysis Center, Research Unit Molecular
Endocrinology and Metabolism, Helmholtz Zentrum München. The
samples were stored at −80°C before analysis. On the day of ex-
traction, the samples were thawed on ice and were randomized
before 100 μl of each sample was pipetted into a well in a 2-ml 96-
well plate. In addition to samples from this study, a pool of samples
of the study was aliquoted into aliquots of 100 μl. The aliquots were
distributed in six wells of the 96-well plate and were extracted as
the samples of the study. Besides those samples, 100 μl of human
reference plasma sample (Seralab) was also extracted as the
samples of the study. These samples served as technical replicates
throughout the data set to assess process variability. In addition,
100 μl of water was extracted as samples of the study and placed in
six wells of each 96-well plate to serve as process blanks.
Protein was precipitated and the metabolites in the samples
were extracted with 475 μl methanol, containing four recovery
standard compounds to monitor the extraction efficiency. After
centrifugation, the supernatant was split into four aliquots of 100 μl
each onto two 96-well microplates. The first two aliquots were used
for LC–MS/MS analysis in positive and negative electrospray ion-
izationmode. Two further aliquots on the second plate were kept as
a reserve. The samples were dried on a TurboVap 96 (Zymark, Sotax).
Before LC–MS/MS in positive ion mode, the samples were recon-
stituted with 50 μl of 0.1% formic acid and those analysed in
negative ion mode with 50 μl of 6.5 mM ammonium bicarbonate, pH
8.0. Reconstitution solvents for both ionization modes contained
further internal standards that allowed monitoring of instrument
performance and also served as retention reference markers. To
minimize human error, liquid handling was performed on a
Hamilton Microlab STAR robot (Hamilton Bonaduz AG).
LC–MS/MS analysis was performed on a linear ion trap LTQ XL
mass spectrometer (Thermo Fisher Scientific GmbH) coupled with a
Waters Acquity UPLC system (Waters GmbH). Two separate columns
(2.1 × 100 mm Waters BEH C18 1.7 μm particle) were used for acidic
(solvent A: 0.1% formic acid in water, solvent B: 0.1% formic acid in
methanol) and for basic (A: 6.5 mM ammonium bicarbonate, pH 8.0,
B: 6.5 mM ammonium bicarbonate in 95% methanol) mobile phase
conditions, optimized for positive and negative electrospray ioni-
zation, respectively. After injection of the sample extracts, the
columns were developed in a gradient of 99.5% A to 98% B in 11 min
run time at 350 μl/min flow rate. The eluent flow was directly
connected to the ESI source of the LTQ XL mass spectrometer. Full-
scan mass spectra (80–1,000 m/z) and data-dependent MS/MS
scans with dynamic exclusion were recorded in turns. Metabo-
lites were annotated by curation of the LC–MS/MS data against
proprietary Metabolon’s chemical database library (Metabolon,
Inc.) based on retention index, precursor mass, and MS/MS spectra.
In this study, 109 metabolites, 63 compounds of known identity
(named biochemical), and 46 compounds of unknown structural
identity (unnamed biochemical) were identified. The unknown
chemicals are indicated by a letter X followed by a number as the
compound identifier. The metabolites were assigned to cellular
pathways based on PubChem, KEGG, and the Human Metabolome
Database.
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Cell collection, homogenization, and targeted metabolomics
The medium was aspirated, the PC-3M cells were quickly washed
twice with 2 ml warm PBS, and their metabolism was subsequently
quenched by the addition of pre-cooled (dry ice) 300 μl extraction
solvent, a 80/20 (vol/vol) methanol/water mixture. Cells were scraped
off the culture vessel using rubber tipped cell scrapers (Sarstedt) and
together with the solvent collected in pre-cooled micro tubes (0.5 ml;
Sarstedt). The culture well was rinsed with another 100 μl extraction
solvent, and the liquid was also transferred to the tube. The samples
were stored at −80°C until further use.
For homogenization, 80-mg glass beads (0.5 mm, VK-05; PeqLab)
were added to the cell samples, which were homogenized using the
Precellys24 homogenizer at 0–3°C for two times over 25 s at 3,720g
with a 5-s pause interval.
To normalize the obtained metabolomics data from cell ho-
mogenates for differences in cell number, the DNA content was
determinedusing a fluorescence-based assay for DNAquantification.
The assay was performed as previously described (Muschet et al,
2016). Briefly, the fluorochrome Hoechst 33342 (10 mg/ml in water;
Life Technologies, Thermo Fisher Scientific) was diluted in PBS to the
final concentration of 20 μg/ml. 80 μl of this dilution was applied to
each well of a black 96-well plate (F96, Nunc; Thermo Fisher Sci-
entific). After brief vortexing of the cell homogenates, 20 μl of the
samplewas added to theHoechst 33342 dilution to gain 100 μl of total
volume per well and mixed by pipetting. Each sample was applied to
the plate in four replicates. 20 μl extraction solvent was used for
blank measurements. The plate was incubated at room temperature
in the dark for 30 min and the fluorescence was read using a GloMax
Multi Detection System (Promega) equipped with an UV filter (λEx 365
nm, λEm 410–460 nm; Promega). Subsequently, the samples were
centrifuged at 4°C and 11,000g for 5 min, and 10 μl of the supernatant
was used for the metabolite quantification.
The targeted metabolomics approach was based on liquid
chromatography-electrospray ionization-tandemmass spectrometry (LC-
ESI-MS/MS) and flow injection-electrospray ionization-tandem mass
spectrometry (FIA-ESI-MS/MS) measurements by AbsoluteIDQ p180 Kit
(BIOCRATES Life Sciences AG). The assay allows simultaneous quantifi-
cation of 188metabolites out of 10 μl plasma and includes free carnitine,
39 acylcarnitines (Cx:y), 21 amino acids (19 proteinogenic + citrulline +
ornithine), 21 biogenic amines, hexoses (sum of hexoses–about 90–95%
glucose), 90 glycerophospholipids (14 lysophosphatidylcholines [lysoPC]
and 76 phosphatidylcholines [PC]), and 15 sphingolipids (SMx:y). The
abbreviations Cx:y are used to describe the total number of carbons and
double bonds of all chains, respectively (for more details see Römisch-
Margl et al (2012)). For the LC-part, compound identification and quan-
tification were based on scheduled multiple reaction monitoring mea-
surements (sMRM). Themethod of AbsoluteIDQp180 Kit has been proven
to be in conformance with the EMEA-Guideline “Guideline on bio-
analytical method validation (21 July, 2011),” which implies proof of re-
producibility within a given error range. Sample preparation and LC–MS/
MS measurements were performed as described in the manufacturer in
manualUM-P180. Analytical specifications for limit of detection (LOD) and
evaluated quantification ranges, further LOD for semiquantitative mea-
surements, identities of quantitative and semiquantitative metabolites,
specificity, potential interferences, linearity, precision and accuracy, re-
producibility, and stability were described in Biocrates manual AS-P180.
The LODs were set to three times the values of the zero samples (ex-
traction solvent). The LLOQ and ULOQ were determined experimentally
by Biocrates.
The assay procedures of the AbsoluteIDQ p180 Kit as well as the
metabolite nomenclature have been described in detail previously
(Römisch-Margl et al, 2012; Zukunft et al, 2013).
Sample handling was performed by a Hamilton Microlab STAR robot
(Hamilton Bonaduz AG) and an Ultravap nitrogen evaporator (Porvair
Sciences), beside standard laboratory equipment. Mass spectrometric
analyses were carried out on an API 4000 triple quadrupole system (Sciex
Deutschland GmbH) equipped with a 1200 Series HPLC (Agilent Tech-
nologies Deutschland GmbH) and a HTC PAL auto sampler (CTC Analytics)
controlledby the softwareAnalyst 1.6. Data evaluation for quantificationof
metabolite concentrations and quality assessment was performed with
the software MultiQuant 3.0.1 (Sciex) and the MetIDQ software package,
which is an integral part of the AbsoluteIDQKit. Metabolite concentrations
were calculated using internal standards and reported in micrometres.
In addition to the investigated samples, five aliquots of a pooled
reference plasma (Ref_Plasma-Hum_PK3) were analysed on each
kit plate. The results of these reference plasma aliquots can be
used for calculation of potential batch effects and data normali-
zation (of different studies).
Mitochondrial toxicity test
Mitochondrial ToxGlo Assay by Promega was used. Cells were
preincubated with either control medium or medium containing
200 μM citrate for 48 h. The assay was performed according to the
manufacturer’s instructions. As recommended, galactose was used
instead of glucose. Highest citrate concentrations were set to be at
10 mM, highest gluconate concentrations were set to be at 600 μM.
Immunohistochemistry
Human tissue (use granted by the Ethics Commission of the University of
Regensburg, number 14-101-0263) was stained with pmCiC specific anti-
body, as described before (Mazurek et al, 2010). Expression of the pmCiC in
cancer cells and cancer-associated stroma was assessed by scanning up
to 20 high-power fields from one slide (Zeiss Microscope Axiovision). The
totalnumberofpositive stained tumourcellswascountedanddepicted in
percentage of all tumour cells. The same method was applied for the
assessment of stromal cells.
To calculate the relative number of the immune cells in liver
metastasis, we have used ImageJ software. Two border and twomiddle
areas of 250 μm by 250 μm were evaluated for each metastasis (four
per experimental group). For each area the number of nuclei and
immune cells were calculated. The results were expressed as a ratio of
the number of immune cells to the total number of nuclei per area.
Scanning electron microscopic imaging
PC-3M cells and fibroblasts were plated on plastic coverslips
(Sarstedt) and left to grow in normal media for 24 h. Themedia were
then changed into experimental media as described before. The
cells were fixed with 2.5% glutaraldehyde for 4 min and washed with
Sörensen buffer (Morphisto). Immediately before HVSEM imaging, the
coverslips were washed in aqua millipore and then exposed to
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ascending series of ethanol (Merck) before critical point drying (Balzers
CPD030). The coverslipsweremountedontoaluminiumstubsusing self-
adhesive carbon discs (Baltic Praeperation). Coverslips were platinum
sputter–coated (Bal-tec SCD 005; Pt-target: Baltic Praeperation) and
introduced into the specimen chamber of the FEI Quanta 400 FEG
electron microscope under high vacuum conditions. The angulation of
the specimen to the beam was 90°. Images were taken using the
Everhart-Thornley detector detector at a working distance of 10mmand
an accelerating voltage of 4 kV at 2,000× originalmagnification. Cells with
round body and a distinct pseudopodium extended in one direction
were considered as ameboidal, cells with no contact with other cells or
cells with no more than 20% contact with others cells were considered
as single.
Lipidomics
Lipids were quantified by direct flow injection electrospray ionization
tandemmass spectrometry (ESI-MS/MS) in positive ion mode using the
analytical setup and strategy described previously (Liebisch et al, 2004,
2006). A fragment ion of m/z 184 was used for phosphatidylcholine
(PC), sphingomyelin (SM) (Liebisch et al, 2004) and lysophosphati-
dylcholine (LPC) (Liebisch et al, 2002). The following neutral losses were
applied: phosphatidylethanolamine (PE) 141, phosphatidylserine (PS)
185, phosphatidylglycerol (PG) 189, and phosphatidylinositol (PI) 277
(Matyash et al, 2008). PE-based plasmalogens (PE P) were analysed
according to the principles described by Zemski-Berry and Murphy
(2004). Sphingosine based ceramides (Cer) and hexosylceramides
(HexCer) were analysed using a fragment ion of m/z 264 (Liebisch et al,
1999). Free cholesterol and cholesteryl ester were quantified using a
fragment ion of m/z 369 after selective derivatization of free cholesterol
(Liebisch et al, 2006). Lipid species were annotated according to the
recently publishedproposal for shorthandnotationof lipid structures that
are derived from mass spectrometry (Liebisch et al, 2013). Glycer-
ophospholipid species annotation was based on the assumption of even
numbered carbon chains only. SM species annotation is based on the
assumption that a sphingoid base with two hydroxyl groups is present.
Statistical analysis for non-targeted metabolomics
Statistical analysis was performed using R (version 3.6.1) (R Core
Team, 2018). Assay-specific quality control was used to correct for
not available (NA) values, by minimum value imputation [min/
sqrt(2)] with a random permutation. The randomizing factor was
located in the range of 0.75 times to 1.25 times min/sqrt(2).
Metabolites which had to be excluded because of having more than
40% NA (entries for which the measurement did not yield any infor-
mation as to the peak area) over all samples were 3,4-hydroxyphenyl-
lactate, 4-acetamidobutanoate, creatinine, γ-glutamylisoleucine,
γ-glutamylleucine, glutathione (oxidized) GSSG, hippurate, N-ace-
tylmethionine, N1-methylguanosine, pro-hydroxy-pro, and pseu-
douridine as well as the unknown metabolites X-15382, X-15484,
X-16266, X-17105, X-17121, and X-18225.
Statistics testing was carried out using Mann–Whitney U test with
Bonferroni correction for multiple testing. Normal data distribution
could not be detected by Shapiro–Wilk test. Significance was set at
the P < 0.05 level, additionally a partial least squares-discriminant
analysis (PLS-DA) was performed in R.
Statistical analysis for targeted metabolomics
NA (entries for which the measurement did not yield any infor-
mation as to the concentration) imputation was performed for
metabolites with less than 40% missing values. Metabolites with
more than 40% missing values were discarded. These excluded
metabolites (or metabolite ratios) were found to be as follows:
ADMA, α-AAA, c4-OH-Pro, Carnosine, DOPA, Dopamine, Nitro-Tyr,
SDMA, Serotonin, PC ae C42:4, SM (OH) C14:1, SM C26:0, ADMA/Arg,
SDMA/Arg, and Serotonin/Trp.
Also, metabolites of the reference samples were checked for
coefficients of variation of more than 25% in their respective ref-
erence samples. The following metabolites were detected to be in
violation of this criterium and subsequently removed:
C5-DC (C6-OH), Histamine, PEA, Spermine, lysoPC a C26:0, lysoPC a C26:
1, lysoPC a C28:0, lysoPC a C28:1, PC aa C24:0, PC aa C26:0, and PC ae C30:1.
Statistics testing was carried out using t test with Benjamini–
Hochberg correction formultiple testing. Significance was set at the P
< 0.05 level. Log-normal data distribution was detected by Shapiro-
Wilks normality test. In addition, a PLS-DA was performed in R.
In vivo experiments
Mouse experiments were conducted according to the regulations of
the State of Bavaria (permission granted by Regierung von Unter-
franken, 55.2-2532.1-34/14 for subcutaneous [Mycielska et al, 2018]
and AZ 55.2-2532-2-805 intrasplenic model, respectively). In the
intrasplenic injection model, L3.6pl cells (1 × 105 cells per animal)
were injected into the lower spleen pole of athymic nude mice (13
animals per group; age: 6–8 wk, Crl:NU(NCr)-Foxn1nu, Charles River).
To avoid side effects of intrasplenic “primary tumours,” the spleen
was removed 15min after tumour cell injection. Treatment started on
day 1 after tumour cell injection and comprised daily intraperitoneal
injection of sodium gluconate (500 mg/kg/d); the control group was
injected with NaCl only. After 24 d the mice were euthanized. Upon
necropsy, livers were dissected and processed for further analyses.
Hepatic tumour load was evaluated by a macroscopic score (0 = no
tumour load; 1 = small singular tumours; 2 = large singular tumours;
3 = confluent tumours in less than half of liver; 4 = confluent tumours
in more than half of liver; 5 = tumours in all liver segments).
The 3D in vivo tumour model (CAM, chorioallantoic membrane) was
carried out as described in previous publications (Feder et al, 2020; Pion
et al, 2020; Troebs et al, 2020). Fertilized chicken eggs were incubated in a
ProConegg incubator (Grumbach)at 37.8°Cand63%humidityunderhourly
rotation for a 4-d period until a window of ~1 × 1 cm was cut into the
eggshell and sealed again with tape. After 4-d incubation, 2 × 106 human
pancreas cancer cells (L3.6pl) suspended in 30 μl Matrigel (Corning) were
grafted onto the CAM. After 2 d of tumour growth, tumourwas daily treated
with gluconate or NaCl (control) for 5 d before tumour excision. Tumour
weight was determined and tumour volumewasmeasured using Keyence
VHX-7000 microscope (Keyence Germany, Neu-Isenburg, (Troebs
et al, 2020)).
Statistical analysis
Statistical analysis was performed using unpaired two-sided t
test unless otherwise stated. Details of statistical analysis for
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non- and targeted metabolomics are included in the Supple-
mental Information.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000903.
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